Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit

Clinical Microbiology and Infection

Volumn 6, Issue 6, 2000, Pages 294-302

  Verwaest, C ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bacterial infections; Imipenem Cilastatin; Intensive care; Meropenem; Resistance

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; MEROPENEM;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BOLUS INJECTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; DRUG TOLERABILITY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS;

BACTERIA (MICROORGANISMS); ENTEROBACTER; ESCHERICHIA COLI; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0034211207     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00082.x     Document Type: Article

References (40)

1. The prevalence of nosocomial infection in intensive care units in Europe
2. Extended spectrum plasmid-mediated β-lactamases
3. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe
4. β-lactam resistance in Gram-negative bacteria: Global trends and clinical impact
5. Meropenem: A microbiological overview
6. Imipenem/cilastatin: An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections
7. Safety profile of meropenem: A review of nearly 5000 patients treated with meropenem
8. The pharmacokinetics of imipenem (thienamycin-formanmidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure
9. APACHE II: A severity of disease classification system
10. Definitions for sepsis and organ failure
11. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study
12. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double-blind clinical trial
13. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections
14. Safety and efficacy of meropenem in patients with septicaemia: A randomised comparison with ceftazidime, alone or combined with amikacin
15. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients
16. Meropenem versus imipenem/cilastatin for the treatment of serious bacterial infections at ICU
17. Prospective, randomised, multi-centre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
18. Pneumonia in the critically ill hospitalized patient
19. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
20. Nosocomial pneumonia in patients receiving continuous mechanical ventilation
21. Nosocomial pneumonia. A multivariate analysis of risk and prognosis
22. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients
23. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
24. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
25. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
26. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients
27. The effect of late-onset ventilator-associated pneumonia in determining patient mortality
28. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin
29. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin
30. Meropenem: Evidence of lack of proconvulsive tendency in mice
31. Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats
32. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of meningitis in adults
33. A randomised comparison of meropenem with cefotaxime for the treatment of bacterial meningitis
34. Imipenem/cilastatin vs amikacin plus piperacillin in the treatment of infections in neutropenic patients: A prospective, randomized, multi-clinic study
35. Beta-lactam antibiotic therapy in febrile granulocytopenic patients
36. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
37. Imipenem/cilastatin as monotherapy in severe infections: Comparison with cefotaxime, in combination with metronidazole and cloxacillin
38. A prospective randomized trial of imipenem/cilastatin vs. clindamycin-tobramycin in the treatment of intra-abdominal and pelvic infections
39. Efficacy and safety of imipenem/cilastatin: A review of world-wide clinical experience